MedPath

The effects of olive-derived hydroxytyrosol intake on LDL-cholesterol oxidative suppression - A systematic review.

Not Applicable
Conditions
Adult volunteers who are healthy or have no more than one mild health disorder (pertaining to blood glucose level, blood pressure or plasma lipid) which is within boundary range and not exceeding boundary range.
Registration Number
JPRN-UMIN000040080
Lead Sponsor
Maruzen Pharmaceuticals Co., LTD.
Brief Summary

We included three articles as result of searching on databases and judging with including criteria. The articles reported result of randomized double-blinded placebo-controlled crossover study which evaluated effect of intake olive derived hydroxytyrosol on blood oxLDL concentrate. We judged heterogeneity of these articles were low and performed meta-analysis. We concluded intake olive derived hydroxytyrosol is significantly decrease blood oxLDL concentrate.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
249
Inclusion Criteria

Not provided

Exclusion Criteria

Literature which does not meet key inclusion criteria will be excluded. Subjects who are suffering from illness, overweight (BMI is 30kg/m2 or more), planning or currently pregnant or breastfeeding, and children (persons under 18 years), will be excluded from this study. If subjects have conditions which exceed limits: Mild hyperlipidemia, Stage 1 hypertension, or Mild hyperglycemia, and/or have more than one of these conditions, the subject is deemed as having an illness and excluded.

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome is the amount of serum oxidized LDL-cholesterol.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath